Challenge to develop the novel cancer therapeutics using Peptide-Drug Conjugate (Is PDC able to lead innovation for anticancer therapeutics?)

Abstract

Present cancer therapeutics has remarkably made progress by clinical application of various kinds of molecular target agents including small molecular compounds and antibody drugs such as Gefitinib and Rituximab over two decades. Clinical achievement brought by these agents has been also changing the concept of drug development for cancer therapeutics. We have focused on developing the Peptide-Drug Conjugate (PDC) based on our novel tumor-homing peptides as a drug carrier, which may have potential for innovating current cancer therapeutics.